FTC and NY sue Daraprim maker over access to samples

Ben Remaly

28 January 2020

The Federal Trade Commission and state of New York have alleged that Vyera Pharmaceuticals broke federal antitrust laws by denying access to samples that competitors needed to replicate its infection-treating drug.

Subscribe to Global Competition Review

Subscribe and start reading now

Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.

Subscribe now

Already have access? Login below

Ben Remaly

View full biography

Author | Senior news reporter, Global Competition Review

[email protected]

Get unlimited access to all Global Competition Review content